COVID-19 vaccine reaches phase-2 trials in China
Xinhua |
Updated: 2020-06-20 21:11
Share
Share - WeChat
BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- Former senior customs official indicted for graft
- From peasant uprising to industrial revolution: hero's hometown revived
- Workers weather desert extremes to complete 'power expressway loop' in southern Xinjiang
- China issues guidelines highlighting independent, impartial judicial work
- For a ranger, no mountain is too high to climb
- Bus driver who died saving tourists honored
